Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Michael S. Weiss
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
therapies for B-cell diseases
|
| gptkbp:focusesOn |
immunology
oncology |
| gptkbp:foundedBy |
Michael S. Weiss
|
| gptkbp:foundedYear |
2012
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
TG Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Russell_2000_Index
|
| gptkbp:notableProduct |
Ublituximab
Umbralisib |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
TGTX
|
| gptkbp:therapeuticArea |
leukemia
multiple sclerosis chronic lymphocytic leukemia |
| gptkbp:website |
https://www.tgtherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:umbralisib
|
| gptkbp:bfsLayer |
6
|